瑞舒伐他汀对经皮冠脉介入诱导心肌损伤的保护作用研究

STUDY ON THE PROTECTIVE EFFECTS OF ROSUVASTATIN ON MYOCARDIAL INJURY INDUCED BY PERCUTANEOUS CORONARY INTERVENTION

目的探讨瑞舒伐他汀对经皮冠脉介入诱导心肌损伤的保护作用。方法选择在渠县人民医院进行经皮冠脉介入术后经心脏核磁共振确诊为诱导心肌损伤的患者140例,分为观察组与对照组。观察组在手术前后给予瑞舒伐他汀,而对照组仅在术后给予基础药物。比较二组患者手术前后的心肌炎症因子的变化情况以及术后并发症。结果观察组术后6个月CRP、TNI、CK-MB的水平分别为(2.78±0.53)mg/L、(0.18±0.04)ng/L、(12.31±0.86)U/L,相比于对照组均显著降低(P<0.05)。观察组与对照组的患者术后的总体并发症发生率为18.6%、38.6%,二组比较差异有统计学意义(P<0.05)。结论瑞舒伐他汀能够改善经皮冠脉介入诱导心肌损伤的症状,并减少并发症,临床应用广泛。

Objective To investigate the effect of rosuvastatin on percutaneous coronary intervention induced myocardial injury. Methods Totally 140 patients with percutaneous coronary intervention induced myocardial injury in Quxian Peoples Hospital from September 2008 to September 2012 were selected as the research subjects and were divided into experimental group and control group. Patients in the experimental group were given rosuvastatin before and after operation, while in the control group were given foundation treatment after operation. Changes of inflammatory factor and the postoperative complications in two groups were compared before and after operation. Results In the experimental group, CRP, TNI, CKMB levels were （2.78 ＋ 0.53） rag/L, （0.18 ＋ 0.04） ng/L, （12.31 -＋ 0.86） U/L in six months after the operation, which were significantly reduced compared with the control group （P〈0.05）. The incidence rate of overall complication of patients in experimental group and the control group were 18.6%, 38. 600 respectively, it was significantly difference （P〈0.05）. Conclusion Rosuvastatin can improve the symptoms of percutaneous coronary intervention induced myocardial injury and reduce the complications, therefore it worthwhile to be widely promoted in clinical application.